IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP1 is a 25.4kD cysteine-rich secreted protein expressed in liver, deciduas, and kidneys and is the most abundant IGF-BP in amniotic fluid. Levels of IGF-BP1 in serum are lowest after food. IGF-BP1 binds to both IGF-I and IGF-II with equal affinity. Phosphorylated IGF-BP1 hinders IGF actions, where as nonphosphorylated IGF-BP1 is stimulatory. Recombinant human IGF-BP1 is a 25.4kD protein consisting of 235aa (Isoform A).
Source
Recombinant protein corresponding to human IGF-BP1, expressed in E.coli.
Biological Activity
Determined by its ability to inhibit IGF-I induced proliferation of MCF-7. The ED50 was found to be 0.5g/ml in the presence of 6ng/ml of human IGF-I.
Endotoxin
<0.1ng/ug (1EU/ug)
AA Sequence
MAPWQCAPCS AEKLALCPPV SASCSEVTRS AGCGCCPMCA LPLGAACGVA TARCARGLSC RALPGEQQPL HALTRGQGAC VQESDASAPH AAEAGSPESP ESTEITEEEL LDNFHLMAPS EEDHSILWDA ISTYDGSKAL HVTNIKKWKE PCRIELYRVV ESLAKAQETS GEEISKFYLP NCNKNGFYHS RQCETSMDGE AGLCWCVYPW NGKRIPGSPE IRGDPNCQIY FNVQN
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Purity
~98% (SDS-PAGE and HPLC)
Form
Supplied as a lyophilized powder.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.